Combinatorial Chemistry Unit, Barcelona Science Park, University of Barcelona, C/Baldiri Reixac 10, 08028 Barcelona, Catalonia, Spain.
Chembiochem. 2013 Mar 4;14(4):499-509. doi: 10.1002/cbic.201200620.
The resistance of malaria parasites to available drugs continues to grow, and this makes the need for new antimalarial therapies pressing. Aminoacyl-tRNA synthetases (ARSs) are essential enzymes and well-established antibacterial targets and so constitute a promising set of targets for the development of new antimalarials. Despite their potential as drug targets, apicoplastic ARSs remain unexplored. We have characterized the lysylation system of Plasmodium falciparum, and designed, synthesized, and tested a set of inhibitors based on the structure of the natural substrate intermediate: lysyl-adenylate. Here we demonstrate that selective inhibition of apicoplastic ARSs is feasible and describe new compounds that that specifically inhibit Plasmodium apicoplastic lysyl-tRNA synthetase and show antimalarial activities in the micromolar range.
疟原虫对抗现有药物的耐药性持续增加,这使得新的抗疟疗法的需求变得迫在眉睫。氨酰-tRNA 合成酶(ARS)是必需的酶,也是成熟的抗菌靶点,因此是开发新抗疟药物的一个有前途的靶点。尽管它们具有作为药物靶点的潜力,但质体 ARS 仍未被探索。我们已经对恶性疟原虫的赖氨酸化系统进行了表征,并基于天然底物中间体:赖氨酸-腺苷酸的结构设计、合成和测试了一组抑制剂。在这里,我们证明了质体 ARS 的选择性抑制是可行的,并描述了新的化合物,这些化合物特异性抑制恶性疟原虫质体赖氨酸-tRNA 合成酶,并在微摩尔范围内显示出抗疟活性。